Que Yaoyao extended warm congratulations on the commencement of the project. Wuxi High-Tech Zone is the core hub for the city’s biopharmaceutical industry, hosting over 850 biopharmaceutical companies and accounting for more than 50% of the city’s industrial scale. It has attracted leading enterprises such as Nutricia and Hengyi Health, and established multiple high-level research platforms, including the Wuxi Institute for Special Food and Nutritional Health, the Wuxi Innovation Research Institute of China Pharmaceutical University, and the SDIC New Quality Protein Bio-manufacturing Innovation Center. The integrated R&D and production cluster for special foods is accelerating its development. This extension of the industrial chain marks a significant step for Walvax Biotechnology in its layout of the medical formula food sector and will further strengthen the special food ecosystem in the zone. Adhering to the principle of “No Challenge Too Great, Meticulous Service Guaranteed,” Wuxi High-Tech Zone will make every effort to ensure the project’s early completion, prompt production launch, and rapid realization of benefits.

Walvax

Walvax is a leading pharmaceutical enterprise in China, integrating the research and development, manufacturing, and sales of human vaccines. Listed on the ChiNext Board of the Shenzhen Stock Exchange in 2010 (stock code: 300142), Walvax ranked sixth globally among vaccine manufacturers (excluding COVID-19 vaccines) in terms of market output value in 2022. Leveraging its leading position in the vaccine sector, particularly its sales and service network extending to grassroots community health service centers, Walvax will further optimize its layout in the broader health industry and establish a benchmark industrial base in the domestic special medical food sector.